Research programme: cancer and influenza virus vaccines - Etubics

Drug Profile

Research programme: cancer and influenza virus vaccines - Etubics

Alternative Names: Adenoviral brachyury vaccine; Adenoviral MUC1 vaccine; Breast cancer vaccine - Etubics; ETBX 051; ETBX 061; Head and neck cancer vaccine - Etubics; HER vaccine - Etubics; HPV-H&N cancer vaccine - Etubics; PSA-targeted vaccine - Etubics; WT-1-targeted vaccine - Etubics

Latest Information Update: 01 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Etubics Corporation
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections; Malignant melanoma
  • No development reported Breast cancer; Head and neck cancer; Prostate cancer

Most Recent Events

  • 08 Jan 2018 NantKwest plans the phase Ib/II QUILT-3.067 trial for Triple negative breast cancer (Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Combination therapy) in USA (NCT03387085)
  • 27 Dec 2017 National Cancer Institute plans a phase I trial for Prostate, Lung, Breast and Colon cancer (Late-stage disease) in USA , (NCT03384316)
  • 29 Jun 2017 NantCell plans the phase Ib/II QUILT-3.051 trial for Ovarian cancer (Combination therapy, Second-line therapy or greater) in September 2017 (NCT03197584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top